Medine.co.uk

Xomolix 2.5mg/Ml Solution For Injection

PACKAGE LEAFLET: INFORMATION FOR THE USER Q ProStfakatl

Xomolix® 2.5 mg/ml solution for injection (Droperidol)

Read all of this leaflet carefully before you start using this medicine because it contains important information for you.

•    Keep this leaflet. You may need to read it again.

•    If you have any further questions, ask your doctor or nurse.

•    This medicine has been prescribed for you. Do not pass it on to others. It may harm them, even if their symptoms are the same as yours.

•    If you get any side effects, talk to your doctor, nurse or pharmacist.

This includes side effects not listed in this leaflet. See section 4.

What is in this leaflet:

1.    What Xomolix is and what it is used for

2.    What you need to know before you are given Xomolix

3.    How you will be given Xomolix

4.    Possible side effects

5.    How to store Xomolix

6.    Contents of the pack and other information

1.    What Xomolix is and what it is used for

Xomolix is a solution of droperidol for injection, which is used to prevent you feeling sick (nausea) or vomiting when you wake up after an operation or when you receive morphine based painkillers after an operation.

The active substance in Xomolix is droperidol. Droperidol belongs to a group of antipsychotics called butyrophenone derivatives.

2.    What you need to know before you are given Xomolix You should not be given Xomolix if you:

•    are allergic (hypersensitive) to the active ingredient droperidol, or any of the other ingredients in Xomolix. (A list of these can be found in Section 6 of this leaflet.)

•    are allergic to a group of medicines used to treat psychiatric disorders, called butyrophenones (e.g. haloperidol, triperidol, benperidol, melperone, domperidone)

•    or anyone in your family have an abnormal electrocardiogram (ECG) heart tracing

•    have low levels of potassium or magnesium in your blood

•    have a pulse rate of less than 55 beats per minute (the doctor or nurse will check this), or are taking any medicines that could cause this to happen

•    have a tumour in your adrenal gland (phaeochromocytoma)

•    are in a coma

•    have Parkinson’s disease

•    have severe depression

Take special care with Xomolix

Before you are given Xomolix injection, you should tell your doctor or nurse if you:

•    have epilepsy, or a history of epilepsy

•    have any heart problems or if you have any history of heart problems

•    have a family history of sudden death

•    have kidney problems (especially if you are on long-term dialysis)

•    have lung disease and any breathing difficulties

•    have prolonged sickness or diarrhoea

•    are taking insulin

•    are taking potassium-wasting diuretics i.e. water tablets (e.g. furosemide or bendroflumethiazide)

•    are taking laxatives

•    are taking glucocorticoids (a type of steroid hormone)

•    If you or someone else in your family has a history of blood clots, as medicines like these have been associated with formation of blood clots

•    are or have been a heavy drinker (of alcohol).

Other medicines and Xomolix

Always tell your doctor or nurse if you are taking or have recently taken any other medicines including those you have obtained without a prescription, as a number of medicines cannot be mixed with droperidol.

Do not take Xomolix if you are taking any of the following medicines:

What the medicine is used for

Medicine (s)

Heart Conditions

Quinidine, disopyramide, procainamide, amiodarone or sotalol

Antibiotics

Erythromycin, clarithromycin, sparfloxacin

Allergies

Astemizole, terfenadine

Mental illnesses e.g. schizophrenia etc.

Chlorpromazine, haloperidol, pimozide, thioridazine

Malaria

Chloroquine, halofantrine

Heartburn

Cisapride

Infection

Pentamidine

Nausea (feeling sick) or vomiting

Domperidone

Opiod dependence; pain

Methadone

Metoclopramide and other neuroleptics should be avoided when taking Xomolix since the risk of movement disorders induced by these medicines is increased.

Droperidol, the active ingredient in Xomolix, can increase the effects of sedatives such as barbiturates, benzodiazepines and morphine based products. It can also increase the effects of medication used to lower high blood pressure (antihypertensives) and a number of other medicines e.g. certain antifungals, antivirals, and antibiotics. Some medicines may also increase the effects of droperidol e.g. cimetidine (for gastric ulcers), ticlopidine (to prevent blood-clotting) and mibefradil (for angina). If you are in any doubt please talk to your doctor or nurse.

Xomolix with food and alcohol

Avoid drinking any alcohol for 24 hours before and after being given Xomolix.

Pregnancy, breast-feeding and fertility

If you are pregnant, inform your doctor who will decide if you should receive Xomolix.

If you are breast-feeding and are going to take Xomolix then it is recommended that you receive only one administration of Xomolix. Breast-feeding can be resumed on waking after your operation.

Ask your doctor for advice before taking any medicine.

Driving and using machines

Droperidol has a major effect on the ability to drive and use machines.

Do not drive or use machinery for at least 24 hours after taking Xomolix.

Xomolix contains sodium

This medicinal product contains less than 1 mmol sodium (23 mg) per 1ml, i.e. essentially ‘sodium-free’.

3. How you will be given Xomolix

Xomolix will be given to you by your doctor by an injection into a vein.

The amount of Xomolix and the way in which it is given will depend on the situation. Your doctor will determine how much Xomolix you need based on a number of things including your weight, age and medical condition.

The usual adult dosage is 0.625 to 1.25 mg, reduced to 0.625 mg for the elderly (over 65 years) and those with renal and hepatic impairment. The dosage in children (2 to 11 years) and adolescents (12 to 18 years) is based on their body weight (10 to 50 microgram/kg) but up to a maximum of 1.25 mg. Xomolix is not recommended in children below 2 years.

If you have any further questions on the use of this product, please ask your doctor or nurse.

4.    Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

Contact your doctor immediately if you experience any increase in your body temperature, muscle stiffness, tremor, rapid swelling of the face or throat, or if you get chest pains after having this medicine.

The following side effects have also been reported: If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor, nurse or pharmacist.

Common side effects (may affect up to 1 in 10 people)

•    Drowsiness

•    Low blood pressure

Uncommon side effects (may affect up to 1 in 100 people)

•    Anxiety

•    Rolling of the eyes

•    Fast heartbeat e.g. more than 100 beats per minute

•    Dizziness

Rare side effects (may affect up to 1 in 1,000 people)

•    Serious allergic reaction known as anaphylaxis or anaphylactic shock

•    Confusion

•    Agitation

•    Irregular heartbeat

•    Rash

•    Neuroleptic malignant syndrome, symptoms include fever, sweating, salivation, muscle stiffness and tremors

Very rare side effects (may affect up to 1 in 10,000 people)

•    Blood disorders (usually diseases affecting red blood cells or platelets). Your doctor can advise you.

•    Change in mood towards sadness, anxiety, depression and irritability

•    Involuntary muscle movements

•    Convulsions or tremors

•    Heart attack (cardiac arrest)

•    Torsade de pointes (life-threatening irregular heartbeat)

•    Prolonged QT interval in ECG (a heart condition affecting the heartbeat)

•    Sudden death

Other side effects which may occur are:

•    Inappropriate anti-diuretic hormone secretion (too much of the hormone is released leading to excess water and low sodium levels in the body)

•    Hallucinations

•    Epileptic seizures

•    Parkinson’s disease

•    Psychomotor hyperactivity

•    Coma

•    Fainting

•    Breathing difficulties

•    Blood clots in the veins, especially in the legs (symptoms include swelling, pain and redness in the leg), which may travel through blood vessels to the lungs causing chest pain and difficulty in breathing. If you notice any of these symptoms seek medical advice immediately.

Reporting of side effects

If you get any of the side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via:

United Kingdom

Yellow Card Scheme

Website: www.mhra.gov.uk/yellowcard

Ireland

HPRA IMB Pharmacovigilance,

Earlsfort Terrace,

IRL - Dublin 2;

Tel: +353 1 6764971;

Fax: +353 1 6762517.

Website: www.imb.iewww.hpra.ie E-mail: medsafety@hpra.ie.

By reporting side effects you can help provide more information on the safety of this medicine.

5.    How to store Xomolix

•    Keep this medicine out of the sight and reach of children.

•    Do not use this medicine after the expiry date which is stated on the carton and ampoule after Exp. The expiry date refers to the last day of that month.

•    Store in the original package.

•    The solution should be used immediately on first opening.

•    Compatibility of droperidol with morphine sulphate in 0.9% sodium chloride (14 days at room temperature) has been demonstrated in plas tic syringes. From a microbiological point of view, the diluted product should be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2 to 8oC, unless dilution has taken place in controlled and validated aseptic conditions.

•    Do not use Xomolix if you notice signs of deterioration. The product should be visually inspected prior to use and only clear solu tions practically free from particles should be used.

•    Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.

6.    Contents of the pack and other information What Xomolix contains

•    The active substance is droperidol, each millilitre of solution contains 2.5mg droperidol.

•    The other ingredients are mannitol, tartaric acid, sodium hydroxide, water for injections.

What Xomolix looks like and contents of the pack

Xomolix is a clear, colourless solution for injection.

The solution is contained in amber coloured glass ampoules. Each ampoule contains 1 millilitre of solution and packaged in cartons containing 10 ampoules.

Marketing Authorisation Holder and Manufacturer Marketing Authorisation Holder    Manufacturer

ProStrakan Limited    Delpharm Tours

Galabank Business Park    rue Paul Langevin

Galashiels    37170 Chambray-les-Tours

TD1 1QH    France

United Kingdom

This medicinal product is authorised in the Member States of the EEA under the following names:

Xomolix

Austria, Czech Republic, Greece, Spain, Hungary, Ireland, Italy, Poland, Portugal, Slovenia, Slovak Republic, UK.

Xomolix 2.5 mg/ml Injektionslosung

Germany

Dehydrobenzperidol

Belgium, Denmark, Finland

Dridol

Iceland and Norway

This leaflet was last revised in November 2014.


LFT-DRO-GB-203


ProStrakan Limited Galabank Business Park, Galashiels, UK, TD1 1QH Tel:    +44 1896 664000

Fax:    +44 1896 664001

Email: artwork@prostrakan.com


O ProStrakan


Please tick the appropriate box:

Amend & Re-Submit

Approved & Proceed

Approved for Print only

Signature

Date

This Proof has been ‘enabled for commenting’ in Acrobat. Please review, add comments if appropriate then click the ‘Send Comments’ button on the toolbar.


Product No:

LFT-DRO-GB-203

Colours Used

Product Name:

Xomolix 2.5mg/1 ml

Black

Item Description:

Leaflet

70% Black

Cutter Ref:

-

Keyline (Do not Print)

Pharmacode:

-

Manufacturer Code:

-

Actual Size:

630 x 127mm

Market:

UK&IE

Language(s):

English

Proof No:

2

Date Issued:

07-Dec-15

Issued By:

-

Font Type:

Helvetica Regular and Helvetica Bold

Font Size:

9pt

Reason for Change:

Update with corrections